JP2006528627A - アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物 - Google Patents

アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物 Download PDF

Info

Publication number
JP2006528627A
JP2006528627A JP2006520939A JP2006520939A JP2006528627A JP 2006528627 A JP2006528627 A JP 2006528627A JP 2006520939 A JP2006520939 A JP 2006520939A JP 2006520939 A JP2006520939 A JP 2006520939A JP 2006528627 A JP2006528627 A JP 2006528627A
Authority
JP
Japan
Prior art keywords
alloreactive
natural killer
cells
killer cells
therapeutic antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006520939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528627A5 (https=
Inventor
アンドレア・ヴェラルディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Perugia
Original Assignee
Universita degli Studi di Perugia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Perugia filed Critical Universita degli Studi di Perugia
Publication of JP2006528627A publication Critical patent/JP2006528627A/ja
Publication of JP2006528627A5 publication Critical patent/JP2006528627A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006520939A 2003-07-24 2004-07-23 アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物 Pending JP2006528627A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48950903P 2003-07-24 2003-07-24
PCT/IB2004/002637 WO2005009466A1 (en) 2003-07-24 2004-07-23 Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells

Publications (2)

Publication Number Publication Date
JP2006528627A true JP2006528627A (ja) 2006-12-21
JP2006528627A5 JP2006528627A5 (https=) 2007-07-26

Family

ID=34102891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006520939A Pending JP2006528627A (ja) 2003-07-24 2004-07-23 アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物

Country Status (4)

Country Link
US (1) US20060240005A1 (https=)
EP (1) EP1648508A1 (https=)
JP (1) JP2006528627A (https=)
WO (1) WO2005009466A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016021720A1 (ja) * 2014-08-07 2016-02-11 学校法人兵庫医科大学 Ｉｌ－１８と分子標的抗体とを併用する癌治療薬
JP2019137696A (ja) * 2019-05-20 2019-08-22 米満　吉和 高活性ｎｋ細胞、およびその利用
US11723924B2 (en) 2017-05-12 2023-08-15 Yoshikazu Yonemitsu Highly active NK cell and use thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095768A1 (en) * 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US20130058921A1 (en) * 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
CA2998292A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
WO2018083080A2 (en) 2016-11-04 2018-05-11 Innate Pharma Nkp46 ligand
AU2018265534A1 (en) * 2017-05-11 2019-10-31 Nantkwest, Inc. Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment
WO2019154509A1 (en) 2018-02-09 2019-08-15 Pupil Labs Gmbh Devices, systems and methods for predicting gaze-related parameters
US11393251B2 (en) 2018-02-09 2022-07-19 Pupil Labs Gmbh Devices, systems and methods for predicting gaze-related parameters
US11556741B2 (en) 2018-02-09 2023-01-17 Pupil Labs Gmbh Devices, systems and methods for predicting gaze-related parameters using a neural network
US11537202B2 (en) 2019-01-16 2022-12-27 Pupil Labs Gmbh Methods for generating calibration data for head-wearable devices and eye tracking system
US11676422B2 (en) 2019-06-05 2023-06-13 Pupil Labs Gmbh Devices, systems and methods for predicting gaze-related parameters
US12353617B2 (en) 2019-06-18 2025-07-08 Pupil Labs Gmbh Systems and methods for determining one or more parameters of a user's eye
EP3973346B1 (en) 2020-02-19 2024-12-25 Pupil Labs GmbH Eye tracking module and head-wearable device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010052762, Ｃａｎｃｅｒ Ｃｈｅｍｏｔｈｅｒ Ｐｈａｒｍａｃｏｌ, 2000, Ｖｏｌ．４６，Ｓｕｐｐｌ, Ｓ３３−Ｓ３６ *
JPN6010052763, Ｓｃｉｅｎｃｅ, 2002, Ｖｏｌ．２９５, ｐ．２０９７−２１００ *
JPN6010052764, Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｈａｅｍａｔｏｌｏｇｙ, 1995, Ｖｏｌ．８９, ｐ．７１２−７１８ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016021720A1 (ja) * 2014-08-07 2016-02-11 学校法人兵庫医科大学 Ｉｌ－１８と分子標的抗体とを併用する癌治療薬
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
US11723924B2 (en) 2017-05-12 2023-08-15 Yoshikazu Yonemitsu Highly active NK cell and use thereof
US12329817B2 (en) 2017-05-12 2025-06-17 Yoshikazu Yonemitsu Highly active NK cell and use thereof
JP2019137696A (ja) * 2019-05-20 2019-08-22 米満　吉和 高活性ｎｋ細胞、およびその利用

Also Published As

Publication number Publication date
EP1648508A1 (en) 2006-04-26
US20060240005A1 (en) 2006-10-26
WO2005009466A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
CN113543799B (zh) 靶向dll3的嵌合抗原受体和结合剂
US20220064255A1 (en) Anti-tcr antibody molecules and uses thereof
US20230048244A1 (en) Anti-tcr antibody molecules and uses thereof
DK1648507T3 (en) PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS
US11945866B2 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
TW202503052A (zh) 嵌合受體和使用彼之方法
JP2006528627A (ja) アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
JP2019516352A (ja) Ｆｌｔ３に対するキメラ受容体及びその使用方法
JP2013014587A (ja) Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
JP2020525010A (ja) 制御性免疫細胞を産生するための方法及びその使用
US11925662B2 (en) Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
JP2005517025A (ja) 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法
TW202019464A (zh) 針對ｓｔｅａｐ１的嵌合受體及其使用方法
US11104738B2 (en) Monoclonal antibodies to human FLT3/FLK2 receptor protein
JP2022540602A (ja) 二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法
TWI917318B (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
JP2018138539A (ja) ＴＣＲａｂ陽性細胞およびＣＤ４５ＲＡ陽性細胞を枯渇させた細胞組成物
HK40063038B (zh) 靶向dll3的嵌合抗原受体和结合剂
MXPA06000841A (es) Metodos y composiciones para aumentar la eficiencia de anticuerpos terapeuticos que utilizan compuestos para potenciar celulas nk

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110802

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111109

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120724